Net (Empagliflozin), according to Mr Column by boehringer ingelheim and eli lilly company joint development of a type 2 sodium synergy of glucose transporters (SGLT - 2, sodium - dependentglucosecotra…
Repaglinide is a diabetes treatment drug, belonging to the non-sulfonylurea insulin-releasing agent class. It was successfully developed by the German company BoehringerIngelheim. In December 1997, it…
Saxagliptin is a type 2 diabetes treatment drug that can stimulate the pancreas to produce more insulin after meals. It was jointly developed by Astrazeneca of the United States and Bristol-Myers Squi…
Lipilidine is a DPP-IV inhibitor. Dpp-iv is an enteroinsulin-stimulating hormone that binds to proteins and exists in many tissues, such as the kidneys, liver, brush margins of the small intestinal me…
alogliptin benzoate, also known as alogliptin, is a serine protease dipeptidyl peptidase IV (DPP-IV) inhibitor developed by Takeda Corporation of Japan. This product can maintain the levels of glucago…
Sitagliptinphosphate (trade name Januvia, code MK-0431), commonly known as sitagliptin, is produced by Merck in the United States. It was approved for marketing by the US Food and Drug Administration …
Insulin glargine is an insulin analogue. On the double chain of insulin, one glycine is replaced respectively and two arginines are added. Therefore, it is called insulin glargine. The addition of the…
Insulin glulisine (HMR 1964) is a fast-acting insulin analogue that mimics the pharmacokinetic and pharmacodynamic characteristics of human physiological insulin. Insulin glulisine can be used in the …
Diabetes is a global chronic metabolic disease that requires lifelong treatment. Under the influence of genetic or environmental factors, pancreatic islet B cells are unable to secrete insulin or secr…
Lyproline insulin is a recombinant human insulin analogue and one of the three rapid-acting insulin analogues. Insulin lispro can be used in the research of hyperglycemia in diabetes.
Gestational diabetes mellitus (gestationaldiabetesmellitus) can lead to a variety of maternal and infant hazards such as fetal distress, hydramnios, severe cases, even cause miscarriage or stillbirth.…
Insulin glargine is a recombinant human insulin analogue, featuring stability, no peak, and a long duration of action. It has low solubility in neutral solutions but can be completely dissolved in aci…
Dete insulin is another new type of soluble long-acting human insulin analogue following insulin glargine. Developed by NovoNordisk, it was launched in Europe in 2004 and approved for the treatment of…
Trulicity (trade name: Trulicity), a long-acting GLP-1 analogue developed by Eli Lilly for one /w subcutaneous injection, was approved in the United States in September 2014 for the treatment of type …
Lisilacil is a glucagon-like peptide-1 (GLP-1) receptor agonist, and GLP-1 is a hormone that helps normalize blood glucose levels. The safety and efficacy of this drug were evaluated in 10 clinical tr…
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea